Characterization of the antibody response to SARS-CoV-2 in a mildly affected pediatric population.
COVID-19
SARS-CoV-2
antibodies
children
humoral immunity
pediatric population
virus neutralization
Journal
Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology
ISSN: 1399-3038
Titre abrégé: Pediatr Allergy Immunol
Pays: England
ID NLM: 9106718
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
revised:
21
01
2022
received:
06
10
2021
accepted:
24
01
2022
entrez:
25
2
2022
pubmed:
26
2
2022
medline:
3
3
2022
Statut:
ppublish
Résumé
While children usually experience a mild course of COVID-19, and a severe disease is more common in adults, the features, specificities, and functionality of the SARS-CoV-2-specific antibody response in the pediatric population are of interest. We performed a detailed analysis of IgG antibodies specific for SARS-CoV-2-derived antigens S and RBD by ELISA in 26 SARS-CoV-2 seropositive schoolchildren with mild or asymptomatic disease course, and in an equally sized, age- and gender-matched control group. Furthermore, a detailed mapping of IgG reactivity to a panel of microarrayed SARS-CoV-2 proteins and S-derived peptides was performed by microarray technology. The capacity of the antibody response to block RBD-ACE2 binding and virus neutralization were assessed. Results were compared with those obtained in an adult COVID-19 convalescent population. After mild COVID-19, anti-S and RBD-specific IgG antibodies were developed by 100% and 84.6% of pediatric subjects, respectively. No difference was observed in regards to symptoms and gender. Mounted antibodies recognized conformational epitopes of the spike protein and were capable to neutralize the virus up to a titer of ≥80 and to inhibit the ACE2-RBD interaction by up to 65%. SARS-CoV-2-specific IgG responses in children were comparable to mildly affected adult patients. SARS-CoV-2 asymptomatic and mildly affected pediatric patients develop a SARS-CoV-2-specific antibody response, which is comparable regarding antigen, epitope recognition, and the ability to inhibit the RBD-ACE2 interaction to that observed in adult patients after mild COVID-19.
Sections du résumé
BACKGROUND
While children usually experience a mild course of COVID-19, and a severe disease is more common in adults, the features, specificities, and functionality of the SARS-CoV-2-specific antibody response in the pediatric population are of interest.
METHODS
We performed a detailed analysis of IgG antibodies specific for SARS-CoV-2-derived antigens S and RBD by ELISA in 26 SARS-CoV-2 seropositive schoolchildren with mild or asymptomatic disease course, and in an equally sized, age- and gender-matched control group. Furthermore, a detailed mapping of IgG reactivity to a panel of microarrayed SARS-CoV-2 proteins and S-derived peptides was performed by microarray technology. The capacity of the antibody response to block RBD-ACE2 binding and virus neutralization were assessed. Results were compared with those obtained in an adult COVID-19 convalescent population.
RESULTS
After mild COVID-19, anti-S and RBD-specific IgG antibodies were developed by 100% and 84.6% of pediatric subjects, respectively. No difference was observed in regards to symptoms and gender. Mounted antibodies recognized conformational epitopes of the spike protein and were capable to neutralize the virus up to a titer of ≥80 and to inhibit the ACE2-RBD interaction by up to 65%. SARS-CoV-2-specific IgG responses in children were comparable to mildly affected adult patients.
CONCLUSION
SARS-CoV-2 asymptomatic and mildly affected pediatric patients develop a SARS-CoV-2-specific antibody response, which is comparable regarding antigen, epitope recognition, and the ability to inhibit the RBD-ACE2 interaction to that observed in adult patients after mild COVID-19.
Identifiants
pubmed: 35212039
doi: 10.1111/pai.13737
pmc: PMC9115525
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Spike Glycoprotein, Coronavirus
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13737Subventions
Organisme : Medical Scientific Fund of the Mayor of the City of Vienna
ID : COVID001
Organisme : Medical Scientific Fund of the Mayor of the City of Vienna
ID : COVID028
Organisme : Österreichische Forschungsförderungsgesellschaft
ID : 35721032
Organisme : Austrian Science Fund
ID : DK-W1248
Informations de copyright
© 2022 The Authors. Pediatric Allergy and Immunology published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
Références
JAMA Pediatr. 2021 Jun 1;175(6):586-593
pubmed: 33480966
Front Med (Lausanne). 2020 Nov 11;7:592629
pubmed: 33262993
Ital J Pediatr. 2021 Apr 15;47(1):90
pubmed: 33858472
Pharmacol Res. 2020 Jul;157:104833
pubmed: 32302706
Nat Commun. 2018 Jun 18;9(1):2382
pubmed: 29915220
Allergy. 2020 Jul;75(7):1730-1741
pubmed: 32077115
Allergy. 2022 Jan;77(1):230-242
pubmed: 34453317
Front Immunol. 2020 Dec 16;11:610300
pubmed: 33391280
Allergy. 2021 Mar;76(3):751-765
pubmed: 33128792
JAMA Pediatr. 2020 Sep 01;174(9):882-889
pubmed: 32320004
Pediatr Allergy Immunol. 2021 May;32(4):762-770
pubmed: 33512035
Allergy. 2021 Feb;76(2):551-561
pubmed: 33040337
J Clin Invest. 2020 Oct 1;130(10):5235-5244
pubmed: 32634129
Allergy. 2021 Mar;76(3):878-883
pubmed: 32734595
Minerva Pediatr (Torino). 2021 Apr 23;:
pubmed: 33890746
Pediatr Allergy Immunol. 2022 Feb;33(2):e13737
pubmed: 35212039
BMC Microbiol. 2021 Jun 26;21(1):194
pubmed: 34174835
Nat Immunol. 2021 Jan;22(1):25-31
pubmed: 33154590
Lab Chip. 2015 Mar 21;15(6):1574-89
pubmed: 25648429
Pediatrics. 2020 Dec;146(6):
pubmed: 32879033
Autoimmun Rev. 2020 Jul;19(7):102567
pubmed: 32376392
Science. 2020 Aug 21;369(6506):1014-1018
pubmed: 32540904
Nature. 2020 May;581(7807):221-224
pubmed: 32225175
Allergy. 2021 Mar;76(3):875-878
pubmed: 32726474
Mol Ther Methods Clin Dev. 2020 May 22;18:1-6
pubmed: 32537478
Nature. 2020 Aug;584(7821):443-449
pubmed: 32668443
Allergy. 2020 Jul;75(7):1564-1581
pubmed: 32396996
Pediatr Pulmonol. 2020 Oct;55(10):2556-2564
pubmed: 32710693
Nature. 2020 Dec;588(7837):315-320
pubmed: 32846427
Eur Respir J. 2020 Apr 23;55(4):
pubmed: 32241833
Amino Acids. 2020 Jul;52(6-7):1063-1065
pubmed: 32627059
Arch Dis Child. 2021 Nov;106(11):1129-1132
pubmed: 33931403